2834 – Page 55 – China Stock Advice

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Adjourned Its 2014 Annual Shareholder Meeting and

[TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), announced that the Company's Annual Meeting of Shareholders for fiscal year ended June 30, 2014 which was scheduled to] []

By info| 2016-03-19T14:35:43+00:00 May 26th, 2015|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 2015-05-26, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF Xi’an, China, May 22, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it had not filed its Quarterly Report on Form 10-Q for] [By Electronic Delivery to: bing@skystarbio-pharmaceutical.com; aorudjev@schiffhardin.com; scramer@skystarbio-pharmaceutical.com May 21, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the “Company”) Nasdaq Symbol: SKBI Dear Mr. Mei: As you know, since we have not received the Company’s Form 10-Q for] []

By info| 2016-03-27T15:16:26+00:00 May 22nd, 2015|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 2015-05-22, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF Xi’an, China,

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF Xi’an, China, May 22, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it had not filed its Quarterly Report on Form 10-Q for] [By Electronic Delivery to: bing@skystarbio-pharmaceutical.com; aorudjev@schiffhardin.com; scramer@skystarbio-pharmaceutical.com May 21, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the “Company”) Nasdaq Symbol: SKBI Dear Mr. Mei: As you know, since we have not received the Company’s Form 10-Q for] []

By info| 2016-03-27T15:19:05+00:00 May 22nd, 2015|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 2015-05-22, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)

[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc.]

By info| 2016-03-24T02:33:22+00:00 May 22nd, 2015|Categories: Chinese Stocks, SEC Original, WX|Tags: 0001403132, 2015-05-22, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, WX|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] NT 10-Q: (Original Filing)

[N/A Former Name if Applicable 4/F Building B Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an, Shaanxi Province, P.R. China City, State and Zip Code PART II -- RULES 12b-25(b) AND (c) x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; (b) The subject annual]

By info| 2016-03-27T15:20:32+00:00 May 18th, 2015|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 2015-05-18, 2834, NT_10-Q, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] NT 10-Q: N/A Former Name if Applicable 4/F Building B

[N/A Former Name if Applicable 4/F Building B Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an, Shaanxi Province, P.R. China City, State and Zip Code PART II -- RULES 12b-25(b) AND (c) x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; (b) The subject annual]

By info| 2016-03-27T15:21:57+00:00 May 18th, 2015|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 2015-05-18, 2834, NT_10-Q, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2015 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By info| 2016-03-28T18:00:17+00:00 May 15th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2015-05-15, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) x March 31, 2015

[FORM 10-Q (Mark One) x March 31, 2015 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By info| 2016-03-28T18:01:18+00:00 May 15th, 2015|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2015-05-15, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2015 Financial Results - Conference call scheduled for May 15, 2015 at 8:00 a.m. ET - BEIJING, May 14, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the first quarter ended March 31, 2015. First Quarter 2015 Financial Highlights (Compared to] []

By info| 2016-03-16T06:26:19+00:00 May 15th, 2015|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2015-05-15, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2015 Financial Results

[Sinovac Reports Unaudited First Quarter 2015 Financial Results - Conference call scheduled for May 15, 2015 at 8:00 a.m. ET - BEIJING, May 14, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the first quarter ended March 31, 2015. First Quarter 2015 Financial Highlights (Compared to] []

By info| 2016-03-16T06:27:15+00:00 May 15th, 2015|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2015-05-15, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments